These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9694047)

  • 1. How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?
    Meyer O
    Clin Rheumatol; 1998; 17(3):179-80. PubMed ID: 9694047
    [No Abstract]   [Full Text] [Related]  

  • 2. [Autoantibodies in systemic sclerosis].
    Genth E; Mierau R
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1758-60. PubMed ID: 22933201
    [No Abstract]   [Full Text] [Related]  

  • 3. [The cutting-edge of medicine; pathogenesis and treatment of systemic sclerosis].
    Sato S
    Nihon Naika Gakkai Zasshi; 2013 May; 102(5):1226-32. PubMed ID: 23847990
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of binding and quantification of human autoantibodies to PDGFRα using a biosensor-based approach.
    Moroncini G; Cuccioloni M; Mozzicafreddo M; Pozniak KN; Grieco A; Paolini C; Tonnini C; Spadoni T; Svegliati S; Funaro A; Angeletti M; Gabrielli A
    Anal Biochem; 2017 Jul; 528():26-33. PubMed ID: 28450104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.
    Boonstra M; Ninaber MK; Ajmone Marsan N; Huizinga TWJ; Scherer HU; de Vries-Bouwstra JK
    Rheumatology (Oxford); 2019 Apr; 58(4):730-732. PubMed ID: 30690619
    [No Abstract]   [Full Text] [Related]  

  • 6. Serological profile of patients with systemic sclerosis.
    Wielosz E; Dryglewska M; Majdan M
    Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?
    Boonstra M; Mertens BJA; Bakker JA; Ninaber MK; Ajmone Marsan N; van der Helm-van Mil AHM; Scherer HU; Huizinga TWJ; de Vries-Bouwstra JK
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):109-117. PubMed ID: 30148428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies.
    Koenig M; Dieudé M; Senécal JL
    Autoimmun Rev; 2008 Sep; 7(8):588-93. PubMed ID: 18617021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interstitial lung manifestations in systemic scleroderma. Correlation between alveolitis, autoantibodies and clinical manifestations].
    Witt C; Hiepe F; Brenke A; Romberg B; Apostoloff E
    Z Arztl Fortbild (Jena); 1994 Nov; 88(11):867-71. PubMed ID: 7839707
    [No Abstract]   [Full Text] [Related]  

  • 10. [Scleroderma associated autoantibodies - clinical and diagnostic relevance].
    Mierau R; Genth E
    Z Rheumatol; 2006 Jul; 65(4):279-84. PubMed ID: 16788839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CXCL4: a new biomarker of diagnosis and severity in systemic sclerosis?].
    Marie I
    Rev Med Interne; 2015 Feb; 36(2):69-72. PubMed ID: 25458865
    [No Abstract]   [Full Text] [Related]  

  • 12. High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies.
    Hamaguchi Y; Matsushita T; Hasegawa M; Ueda-Hayakawa I; Sato S; Takehara K; Fujimoto M
    Mod Rheumatol; 2015 Sep; 25(5):798-801. PubMed ID: 24252018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autoantibodies in systemic sclerosis: clinical interest and diagnosis approach].
    Admou B; Essaadouni L; Amal S; Arji N; Chabaa L; El Aouad R
    Ann Biol Clin (Paris); 2009; 67(3):273-81. PubMed ID: 19411229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New ACR EULAR guidelines for systemic sclerosis classification.
    Johnson SR
    Curr Rheumatol Rep; 2015 May; 17(5):32. PubMed ID: 25874345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Laboratory diagnostics for systemic sclerosis].
    Mierau R; Roers A; Genth E
    Z Rheumatol; 2007 May; 66(3):206, 208-11. PubMed ID: 17354003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].
    Johanet C; Agostini MM; Vayssairat M; Abuaf N
    Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis.
    Antonioli CM; Danieli E; Airò P; Cattaneo R; Tincani A
    Ann Rheum Dis; 2003 Jun; 62(6):589-90. PubMed ID: 12759304
    [No Abstract]   [Full Text] [Related]  

  • 18. Autoantibodies in systemic sclerosis.
    Mehra S; Walker J; Patterson K; Fritzler MJ
    Autoimmun Rev; 2013 Jan; 12(3):340-54. PubMed ID: 22743034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic autoantibodies in systemic sclerosis.
    Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
    Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies and clinical subsets: relevance to scleroderma.
    Maddison PJ
    Wien Klin Wochenschr; 2000 Aug; 112(15-16):684-6. PubMed ID: 11020957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.